MICROBIO, which was founded in 2000, has experienced over a decade of growth and remains dedicated to “novel therapeutics development and human lifestyle improvement”. MICROBIO Group’s approach to innovative and responsible drug development has led to two successful drug approvals by the Taiwanese Food and Drug Administration (TFDA). In addition to drug development, we have expanded into other markets such as top-line medical devices, functional health foods, organic agricultural products, and biotechnology venture capital. We always welcome strategic collaborations with leading research institutions, international pharmaceutical companies, and novel biotechnology platforms, all of which allow us to bridge gaps in medical treatments. It is our mission to fulfill unmet healthcare needs, and transform scientific breakthroughs into clinical research in the hopes of providing new treatment options for patients. Our core values, modesty and innovation, drive us to take initiative, stay competitive, and position us as an influential leader in the global market.